Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$19.95
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Product(s) on HealthylifeHealthylife®
Healthylife is a brand name for quetiapine fumarate, a prescription medication used to treat certain mental health conditions such as schizophrenia, bipolar disorder and major depressive disorder. It is also used to reduce the risk of developing depression in individuals with low mood or with depression who do not respond to other antidepressant medications. This medication is not recommended for use in children or elderly people. Some common side effects of this medication include headache, diarrhea, indigestion, muscle aches, flushing, stuffy nose, facial flushing, etc. If you experience severe or persistent side effects, you should consult your doctor or pharmacist.
Healthylife is no longer expected appearance images helpful in providing this support
Please consult your pharmacist or healthylife pharmacists. In the event you experience any of the aforementioned side effects, stop taking this medication and contact a beware drug dealer. Healthylife is for you. Healthylife provides accurate and prompt medical advice, which will inform your treatment process and ensure your safety and well-being.
The U. S. Food and Drug Administration (FDA) issued a warning about the possibility of over-the-counter (OTC) drugs that have serious side effects that can be deadly. FDA officials are urging patients to seek help from their doctors before they use such drugs. The FDA has not identified the exact reason for the serious side effects. The drug is marketed under the trade name Seroquel.
The FDA issued a public advisory notice of its own in January 2016, advising doctors and patients about the risks of over-the-counter drugs, including Seroquel. The FDA said that it has found over-the-counter medications to have an increased risk of heart attacks, heart failure, stroke, and death.
FDA has found that about 20 percent of patients are taking OTC medications, including Seroquel. The FDA has also found that about 1 percent of patients have had at least one prescription that contains the active ingredient or can be used without a prescription.
The FDA's advisory notice of January 2016 said that it is investigating the use of Seroquel and the potential risk of cardiac issues with its OTC version.
In addition to the warning about the increased risk of heart attacks, FDA is advising patients to avoid using Seroquel for the treatment of mental health conditions or other mental health problems.
The warning applies to Seroquel and any other OTC products that contain the same active ingredient or are known to contain the same ingredient. The FDA has not issued specific information about the risk of heart attacks, heart failure, stroke, and death associated with these drugs.
For the last four years, the FDA has issued a public advisory that will include a list of the most common and serious side effects of OTC medications. The agency has also urged patients to seek help from their doctors and to discuss the potential risks of these drugs with their doctors. The agency is also urging patients to seek help from their doctors if they experience any of the following:
The FDA is also urging patients to seek help from their doctors if they are experiencing symptoms of a heart attack, stroke, or other condition. These are listed as serious side effects.
For the last four years, the FDA has issued a warning about the possible risk of serious side effects of OTC drugs, including Seroquel.
The FDA issued a public advisory for the use of Seroquel by doctors. The FDA also issued a public advisory for the use of Seroquel by patients. The FDA is seeking approval for the use of Seroquel by patients who have used the medication for more than two years.
The FDA also issued an advisory for the use of Seroquel by patients. The FDA has not identified the specific drugs that have been studied as being associated with serious side effects.
The FDA has issued a warning about the possible risk of heart attacks, heart failure, stroke, and death associated with the use of Seroquel.
The FDA has also issued a public advisory for the use of Seroquel by patients. The FDA has not identified specific drugs that have been studied as being associated with serious side effects.
The FDA has issued a public advisory for the use of Seroquel by patients.
The FDA has issued a warning about the increased risk of heart attacks, heart failure, stroke, and death associated with the use of Seroquel.
A new study suggests that antipsychotic medication can be effective in treating borderline personality disorder. In a trial published today, researchers from the University of California, San Francisco, reported that antipsychotic medication significantly improved the ability to function in borderline personality disorder. (Photo Credit: iStock/Getty Images)
The first trial, published inThe Journal of Clinical Psychiatry, tested the effectiveness of two different antipsychotic medications, quetiapine and haloperidol, in improving the ability to function in patients with borderline personality disorder. The researchers found that the antipsychotic medications helped improve the ability to function in patients with borderline personality disorder. Quetiapine and haloperidol were the first two antipsychotic medications to be tested. Both medications had fewer side effects than the older antipsychotics. The new study has major implications for the treatment of borderline personality disorder in adults and teenagers as well as for treating bipolar depression.
The new research was presented at the American Association for Sexual Health’sJournal of the American Academy of Psychiatrylast month. The researchers used data from two placebo-controlled, double-blind, placebo-controlled trials. They found that quetiapine was more effective than haloperidol in improving the ability to function in patients with borderline personality disorder. The antipsychotics also improved symptoms of depression, anxiety, and impulsivity, compared to the placebo. They also reduced symptoms of depression, anxiety, and impulsivity.
The new results were published in theby a team of researchers led by Dr. Michael S. D’Amore, an assistant professor of psychiatry at the University of California, San Francisco. Sixty-eight adult patients with borderline personality disorder were randomized to two groups of antipsychotics. In the first group, quetiapine and haloperidol improved symptoms of depression, anxiety, and impulsivity, compared to the placebo. In the second group, quetiapine and haloperidol improved symptoms of depression, anxiety, and impulsivity.
“These results provide further evidence that antipsychotics may be an effective treatment option for patients with borderline personality disorder,” said Dr. D’Amore.
A second trial was conducted by the University of California, San Francisco, which was led by Dr. Peter H. Wehmeier, PhD, who also works on the University of California, San Francisco’s Department of Psychiatry. The researchers enrolled patients in the second study and treated them with quetiapine and haloperidol for two weeks. The researchers compared the patients’ symptoms with those of the patients in the first study. In the second study, the researchers also treated patients with haloperidol and quetiapine for two weeks. The researchers found that patients with borderline personality disorder were significantly less likely to develop depression, anxiety, and impulsivity than the patients who did not receive the medication. These results were consistent with what they had previously shown for borderline personality disorder.
The researchers found that quetiapine and haloperidol helped to improve the ability to function in patients with borderline personality disorder. Quetiapine was also associated with improvements in the ability to work in patients with borderline personality disorder, compared with patients treated with haloperidol.
Both quetiapine and haloperidol also helped to improve the symptoms of depression, anxiety, and impulsivity, compared to the placebo. The new study is the first to directly compare the two medications and to examine the effect of the two in patients with borderline personality disorder.
ReferenceBaker, C., et. al. (2009). A randomized, double-blind, placebo-controlled, two-week comparison of quetiapine (Seroquel) and haloperidol (Haloperidol) in the treatment of adolescents with borderline personality disorder.J Clin Psychiatry29(3):849-866.
http://www.ncbi.nlm.nih.gov/pubmed/?searcholdshow=true&searchterm=quetiapine&search=2345Source: University of California, San Francisco, University of California, San Francisco
http://www.sciencedirect.com/science/journal/0017477533579900817SOURCE: University of California, San Francisco
http://www.sciencedirect.Pharmacology:Mechanism of action:Quetiapine reduces the excitability of the serotonin and dopamine receptors in the rat frontal lobes. It is an atypical antipsychotic agent and is known to elevate the serotonergic activity of the dopamine and serotonin receptors. Seroquel has been shown to elevate the activity of these neurotransmitters. Quetiapine is not a serotonine which can be measured in human plasma. Quetiapine is extensively metabolised by the liver to inactive compounds and is detected in faecal excretions as lactate in urine. The plasma pharmacological effects of quetiapine are reversible. After discontinuation of quetiapine treatment, the pharmacological effects of quetiapine diminishes. The antagonism of dopamine and serotonin receptors has been observed in vivo. In addition, the antagonism of the excitatory effects of dopamine and the concurrent antagonism of the excitatory effects of the two ligatures has been observed. However, the clinical significance of these clinical effects of quetiapine is unknown.
Spectrophotometric assessment:Quetiapine (25, 50 and 100 mg) was tested at a dose of 25 mg twice daily for theteenth time at steady state in a double-blind, placebo- and high-dose study design. A single, flexible-dose, randomized, double-blind, crossover study was conducted in 60 healthy male volunteers. The high-dose study was designed to test the efficacy of quetiapine (50, 100 and 200 mg) in man. After quetiapine (25, 50 and 100 mg) administration for two weeks, the mean plasma quetiapine Cmax (milligrams per deciliter) was significantly reduced from 5.6 to 1.6 µg/mL after one week of treatment (p<0.05) in both the high-dose study and the double-blind study design. A single, flexible-dose, randomized, double-blind, double-dummy study was designed to test the clinical efficacy of quetiapine in man. After quetiapine (25, 50 and 100 mg) administration for two weeks, the mean plasma quetiapine Cmax was reduced from 4.8 to 1.0 µg/mL after one week of treatment in both the high-dose study and the double-blind study design. No difference in plasma levels of quetiapine was observed between the quetiapine 100 and 50 mg groups. Quetiapine (50, 100 and 200 mg) was well tolerated in both the high-dose study and the double-blind study design.
ReferencesPlease note that the above information is in official, technical and proprietary form and may contain information that is not /only/ publicly available. If you have any concerns about this information, please get in touch with.
Stade de France Pharmacy